MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
Canada - TSX:MBX - CA59501P1045 - Common Stock
0.245 CAD
-0.02 (-7.55%)
We assign a fundamental rating of 6 out of 10 to MBX. MBX was compared to 22 industry peers in the Biotechnology industry. While MBX has a great profitability rating, there are some minor concerns on its financial health. MBX is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make MBX suitable for growth investing!
1. Profitability
1.1 Basic Checks
MBX had negative earnings in the past year.
In the past year MBX had a positive cash flow from operations.
In multiple years MBX reported negative net income over the last 5 years.
Of the past 5 years MBX 4 years had a positive operating cash flow.
1.2 Ratios
MBX's Return On Assets of -0.85% is amongst the best of the industry. MBX outperforms 95.45% of its industry peers.
The Return On Equity of MBX (-1.11%) is better than 95.45% of its industry peers.
MBX has a better Return On Invested Capital (1.38%) than 95.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -1.11% | ||
| ROIC | 1.38% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of MBX has grown nicely.
Looking at the Operating Margin, with a value of 3.26%, MBX belongs to the top of the industry, outperforming 95.45% of the companies in the same industry.
MBX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 55.77%, MBX belongs to the top of the industry, outperforming 95.45% of the companies in the same industry.
MBX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.26% | ||
| PM (TTM) | N/A | ||
| GM | 55.77% |
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MBX is destroying value.
Compared to 1 year ago, MBX has less shares outstanding
The number of shares outstanding for MBX has been increased compared to 5 years ago.
The debt/assets ratio for MBX has been reduced compared to a year ago.
2.2 Solvency
MBX has an Altman-Z score of 2.52. This is not the best score and indicates that MBX is in the grey zone with still only limited risk for bankruptcy at the moment.
MBX has a better Altman-Z score (2.52) than 86.36% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that MBX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.21, MBX perfoms like the industry average, outperforming 59.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.52 |
ROIC/WACC0.19
WACC7.48%
2.3 Liquidity
A Current Ratio of 9.73 indicates that MBX has no problem at all paying its short term obligations.
MBX has a better Current ratio (9.73) than 95.45% of its industry peers.
MBX has a Quick Ratio of 6.15. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX's Quick ratio of 6.15 is amongst the best of the industry. MBX outperforms 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.73 | ||
| Quick Ratio | 6.15 |
3. Growth
3.1 Past
MBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -106.48%.
The Earnings Per Share has been growing by 8.58% on average over the past years. This is quite good.
MBX shows a decrease in Revenue. In the last year, the revenue decreased by -9.53%.
Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 13.62% on average per year.
EPS 1Y (TTM)-106.48%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-750%
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-31.37%
3.2 Future
Based on estimates for the next years, MBX will show a very strong growth in Earnings Per Share. The EPS will grow by 51.83% on average per year.
MBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.86% yearly.
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Forward Earnings ratio of 6.06, the valuation of MBX can be described as very cheap.
Based on the Price/Forward Earnings ratio, MBX is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, MBX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.06 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MBX is valued cheaply inside the industry as 95.45% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 13.06 |
4.3 Compensation for Growth
MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX has a very decent profitability rating, which may justify a higher PE ratio.
MBX's earnings are expected to grow with 51.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y51.83%
5. Dividend
5.1 Amount
No dividends for MBX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MBX (11/14/2025, 7:00:00 PM)
0.245
-0.02 (-7.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.73%
Ins Owner ChangeN/A
Market Cap34.18M
Revenue(TTM)21.14M
Net Income(TTM)-324.80K
Analysts80
Price Target0.92 (275.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.06 | ||
| P/S | 1.62 | ||
| P/FCF | N/A | ||
| P/OCF | 56.81 | ||
| P/B | 1.17 | ||
| P/tB | 1.34 | ||
| EV/EBITDA | 13.06 |
EPS(TTM)0
EYN/A
EPS(NY)0.04
Fwd EY16.49%
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFY1.76%
SpS0.15
BVpS0.21
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -1.11% | ||
| ROCE | 1.92% | ||
| ROIC | 1.38% | ||
| ROICexc | 2.09% | ||
| ROICexgc | 2.5% | ||
| OM | 3.26% | ||
| PM (TTM) | N/A | ||
| GM | 55.77% | ||
| FCFM | N/A |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-16.73%
ROICexgc growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score3
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 51.1% | ||
| Cap/Sales | 4.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 25.12% | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.73 | ||
| Quick Ratio | 6.15 | ||
| Altman-Z | 2.52 |
F-Score3
WACC7.48%
ROIC/WACC0.19
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-106.48%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-750%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-31.37%
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
EBIT growth 1Y-68.79%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-29.47%
EBIT Next 3Y21.52%
EBIT Next 5YN/A
FCF growth 1Y83.08%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y17.98%
OCF growth 3Y27.25%
OCF growth 5Y155.41%
MICROBIX BIOSYSTEMS INC / MBX.CA FAQ
What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MBX.CA.
Can you provide the valuation status for MICROBIX BIOSYSTEMS INC?
ChartMill assigns a valuation rating of 6 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.
What is the profitability of MBX stock?
MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 7 / 10.
What is the earnings growth outlook for MICROBIX BIOSYSTEMS INC?
The Earnings per Share (EPS) of MICROBIX BIOSYSTEMS INC (MBX.CA) is expected to grow by 50% in the next year.